Zanaflex

Basic Zanaflex Information

• INN (International Nonproprietary Name): Tizanidine.
• Brand Names Available In Australia: Zanaflex, Sirdalud, Tizanidina, Ontralfy and multiple generics are listed globally; local availability and specific presentations in Australia vary and should be checked on the TGA ARTG and local pharmacy stock.
• ATC Code: M03BX02.
• Forms & Dosages: Tablets 2 mg and 4 mg; capsules 2 mg, 4 mg and 6 mg; some sustained‑release 6 mg preparations exist depending on brand.
• Manufacturers In Australia: Not specified in the RAW DATA; global manufacturers include Novartis (Sirdalud) and Acorda Therapeutics (Zanaflex), with many generics from Accord Healthcare, Apotex, Teva and Mylan referenced.
• Registration Status In Australia: Not specified in the RAW DATA for individual ARTG entries; tizanidine is prescription‑only in virtually all markets and clinicians should verify TGA ARTG listings for local registration details.
• OTC / Rx Classification: Prescription (Rx) — not over the counter.

Critical Warnings & Restrictions (Safety First)

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Tizanidine is prescription‑only and requires clinician oversight before use.

Absolute contraindications: do not use with fluvoxamine or ciprofloxacin, in known allergy to tizanidine, or in severe hepatic impairment.

In Australia apply extra caution in older patients because they have increased risk of sedation, hypotension and bradycardia.

Exercise caution in people with hepatic or renal impairment, in pregnant or breastfeeding people where safety data are limited, and in patients with significant cardiovascular disease.

• High‑Risk Screening:
  • Age over 65 years.
  • Known liver disease or elevated liver enzymes.
  • Renal impairment or dialysis.
  • Cardiac disease (arrhythmia, hypotension, bradycardia).
  • Concurrent CNS depressant use (opioids, benzodiazepines) or antihypertensives.
  • Pregnancy or breastfeeding status unclear or positive.
  • History of falls, orthostatic hypotension or syncope.

Baseline Tests (Checklist):

• Blood pressure and resting heart rate measurement before initiation.
• Liver function tests (ALT, AST, bilirubin) prior to starting.
• Medication review for interacting drugs (notably fluvoxamine, ciprofloxacin, strong CYP1A2 inhibitors).
• Renal function baseline where clinically indicated.

Monitoring Schedule (Checklist):

• Blood pressure and heart rate: at baseline, during titration and at regular follow‑up visits.
• Liver function tests: baseline, within weeks of initiation and periodically thereafter if long‑term use.
• Clinical review for sedation, dizziness and fall risk during and after each dose increase.

Patient Protection Measures:

• Provide a clear written action plan for dizziness or fall risk, including when to sit or lie down if lightheaded and when to seek care.
• Advise strict avoidance of alcohol and other sedatives while on tizanidine.
• Provide instructions for gradual dose taper if stopping is required to avoid rebound hypertension and withdrawal effects.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Tizanidine commonly causes drowsiness and dizziness and can impair reaction times.

Patients must not drive or operate heavy machinery until they know how the drug affects them.

Where a person has a safety‑critical role at work they should inform their employer and arrange fitness‑for‑duty assessment in line with Australian workplace safety laws.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: No until you know how it affects you.

Tizanidine commonly causes drowsiness and dizziness, so do not drive or operate heavy machinery until you are confident you are alert and safe.

Australian road and workplace safety law requires fitness for duty, and driving while sedated can be illegal and dangerous.

Always follow GP or pharmacist advice about when it is safe to resume driving.

Usage Basics

INN, Brand Names Available In Australia

International Nonproprietary Name: tizanidine.

• Common Brand Names: Zanaflex, Sirdalud, Tizanidina, Ontralfy and various generics.
• Typical Presentations: Tablets 2 mg and 4 mg; capsules 2 mg, 4 mg, 6 mg; some SR 6 mg formulations with brand variation.

Packaging differs by brand; Zanaflex® is commonly packaged as 2, 4 and 6 mg capsules and some tablets are marketed as 2 mg or 4 mg — always check the product SPC for the exact presentation.

For local ARTG entries versus imported brands a simple table in clinic records is useful: ARTG entry, brand name, strength and pack size, importer.

Legal Classification (TGA‑Approved, PBS‑Listed)

Tizanidine is prescription‑only in virtually all markets.

Clinicians and pharmacists must confirm TGA approval and PBS listing for specific brand presentations before advising about subsidy or prescribing authority requirements.

Where a product is not PBS‑listed consider cost discussion and alternative PBS‑subsidised agents.

• Clinician/Pharmacist Verification Checklist:
  • Check ARTG entry for the product and presentation.
  • Confirm PBS item code and whether authority prescription is required.
  • Consider Special Access Scheme for importation if local supply is unavailable.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

Typical adult initiation is 2 mg, given up to three times daily, with slow upward titration by 2–4 mg every 4–7 days as tolerated.

Maximum reported daily dose is 36 mg, though individual response and tolerability guide the practical ceiling.

Short‑term use is often recommended around physiotherapy or activity, while some chronic cases require ongoing daily therapy with close supervision.

Titration Checklist:

• Start low and increase slowly by 2–4 mg every 4–7 days only if tolerated.
• Assess BP and sedation after each increase.
• Stop or reduce dose if excessive drowsiness, dizziness or hypotension occurs.

Adjustments For Comorbidities

Elderly patients should start at the low end and titrate very slowly because of increased sensitivity to hypotension and sedation.

Use in liver impairment warrants extreme caution and lower doses because tizanidine is metabolised in the liver.

In renal impairment consider lower doses and increased clinical monitoring for accumulation and toxicity.

Children: safety and efficacy are not established and use should be avoided unless under specialist paediatric guidance.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember unless it is close to the next scheduled dose.

Do not double up doses to make up for a missed dose.

If you are unsure what to do, contact your pharmacist or GP for advice.

• Missed Dose Checklist:
  • Take as soon as remembered if more than several hours from next dose.
  • Skip if close to next dose time; resume normal schedule.
  • Document missed doses and report frequent misses to your clinician.
• Overdose Actions: Seek urgent medical care for symptoms such as severe drowsiness, slow pulse, breathing difficulty or loss of consciousness.

Interaction Chart (Practical Quick Reference)

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Alcohol potentiates central nervous system depression and increases the risk of falls and respiratory depression, so avoid alcohol while taking tizanidine.

Caffeine will not reliably prevent sedation, so patients who habitually drink strong coffee, energy drinks or take stimulants should still expect sedative effects.

Dosing with or without food should follow prescribing advice because food timing can alter absorption and side effects for some brands.

Common Drug Conflicts

Absolute contraindications are coadministration with fluvoxamine and ciprofloxacin because these interactions markedly increase tizanidine levels and raise toxicity risk.

Significant interactions include other CNS depressants (opioids, benzodiazepines), antihypertensives (additive hypotension) and some CYP1A2 inhibitors.

High‑Risk Combinations (Bullet List):

• Fluvoxamine — avoid.
• Ciprofloxacin — avoid.
• Concurrent opioids or benzodiazepines — monitor and consider alternatives.
• Strong CYP1A2 inhibitors — consider alternatives or dose reduction.

Checklist For Each Visit: review the full medication list, look for new antibiotics or antidepressants, and reconcile over‑the‑counter products and supplements.

User Reports & Trends (Australian Patient Experience)

Patients commonly ask whether zanaflex will help with daily spasm and how much sedation to expect.

Reviews and forums in Australia show mixed but consistent themes in patient experience.

• Commonly Reported Benefits: modest reduction in muscle tone and fewer spasms during activity.
• Commonly Reported Harms: sedation, dry mouth and dizziness are the most frequent complaints.
• Access Themes: rural patients report travel and stock issues while urban patients report better access through major chains and telehealth.
• Price Sensitivity: Australians commonly compare retailers and expect PBS subsidy where possible.

Clinicians are advised to record patient‑reported outcomes and consider dosing at night to mitigate daytime sedation in suitable patients.

Access & Purchase Options (Australia)

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

Tizanidine is prescription‑only and major Australian pharmacy chains commonly dispense prescription tizanidine when the product is on the ARTG and in stock.

Availability of brands (Zanaflex or generics) varies by retailer and distribution; patients should check stock and pricing in advance.

Online Pharmacies And Telehealth E‑Prescriptions

Legitimate online pharmacies and telehealth services can supply tizanidine with a valid e‑prescription.

Verify the pharmacy is Australian‑registered and that prescriptions meet TGA and PBS requirements before ordering.

• Safe Online Purchase Checklist:
  • Confirm pharmacy registration and Australian contact details.
  • Require a valid prescription from an Australian prescriber.
  • Confirm brand/formulation and pack size before payment.
  • Check delivery conditions and avoid exposure to high heat during transit.

In our online pharmacy, zanaflex is available with a valid prescription, with discreet delivery to Australia in 9–21 days.

Mechanism & Pharmacology (Clear, Clinician‑Friendly)

Simplified Explanation

Tizanidine is a centrally acting alpha‑2 adrenergic agonist that reduces spasticity by decreasing excitatory neurotransmitter release in the spinal cord.

Clinically this reduces muscle tone and spasms, and can help during physiotherapy and activity in conditions such as multiple sclerosis and spinal cord injury.

Clinical Terms

ATC code: M03BX02.

Tizanidine is metabolised in the liver via CYP pathways and has a relatively short half‑life, which explains the need for multiple daily dosing and the potential for rebound effects if stopped abruptly.

• Definitions:
  • Alpha‑2 Agonist — reduces presynaptic release of excitatory neurotransmitters.
  • Half‑Life — relatively short, requiring divided dosing.
  • CYP1A2 — enzyme implicated in tizanidine metabolism and interactions.
  • Rebound Hypertension — possible if drug is stopped suddenly.

Indications & Off‑Label Uses

Approved Indications By TGA

The principal indication internationally is the management of spasticity, for example in multiple sclerosis and spinal cord injury.

Verify the exact wording of approved indications on the TGA ARTG for any product before prescribing in Australia.

Off‑Label Uses In Australian Clinical Practice

Off‑label uses may include short‑term relief of acute muscle spasm in selected patients, though evidence is mixed.

Clinicians commonly consider alternatives such as baclofen or benzodiazepines depending on the clinical picture.

• Accepted Indications And Off‑Label Scenarios:
  • Chronic spasticity due to MS or spinal injury — accepted use.
  • Short‑term muscle spasm with physiotherapy — occasional off‑label use.

Off‑Label Prescribing Checklist:

• Document rationale for off‑label use.
• Explain risks and alternatives to the patient and gain informed consent.
• Set a review date and monitoring plan.

Key Clinical Findings (Evidence Summary)

Randomised trials and systematic reviews show tizanidine provides modest improvement in spasticity scores compared with placebo in selected populations, balanced against sedation and hypotension risks.

Comparative data versus baclofen and other agents show differing adverse‑effect profiles rather than clear superiority of any single drug.

Safety signals such as hepatic enzyme changes and bradycardia necessitate baseline and ongoing monitoring.

Clinicians should check recent Australian and international guideline updates and trials (including material from 2022–2024) before decisions, as evidence evolves.

• Practice Implications:
  • Monitor BP and LFTs at baseline and during treatment.
  • Use slow titration to reduce adverse effects.
  • Consider switching agents if sedation or hypotension limit function.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Pros And Cons Checklist

• Pros Of Tizanidine: short half‑life allows flexible dosing; useful for specific spasticity patterns.
• Cons Of Tizanidine: sedation, hypotension, important drug interactions (fluvoxamine, ciprofloxacin), hepatic metabolism concerns.
• Baclofen Pros/Cons: less hypotension than tizanidine in some patients but may still cause sedation and risk of severe withdrawal if stopped abruptly.
• Choosing An Agent Checklist:
  • Indication and spasticity pattern.
  • Comorbidities (liver, kidney, heart).
  • Concurrent medications and interaction risk.
  • PBS access and patient cost preference.

Common Questions (Pharmacy Consultation FAQs)

• Can I take it with alcohol? No — avoid alcohol due to increased sedation and risk of respiratory depression.
• Is it safe in pregnancy/breastfeeding? Data are limited; use only if benefits outweigh risks and after specialist review.
• How quickly will it work? Effects can be noticed within hours to days; full benefit may take longer during titration.
• Can I stop suddenly? No — taper gradually to avoid rebound hypertension and withdrawal symptoms.
• What are typical side‑effects? Drowsiness, dry mouth, dizziness, hypotension, muscle weakness.

When To Call GP Or Emergency (Checklist):

• Severe drowsiness or inability to stay awake.
• Fainting, collapse or recurrent falls.
• Very slow pulse or breathing difficulty.
• Severe abdominal pain, jaundice or other signs of liver injury.

Price & Access Comparison Table (How To Present To Patients)

Table Columns & Data Points To Include

For patient handouts use a standard comparison table with these columns.

• Source (pharmacy/online).
• Brand/generic name.
• Pack size and strength.
• Typical price range in AUD.
• PBS subsidy (Yes/No and item code if applicable).
• Prescription required (Yes).
• Notes on stock or lead‑time.

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

Prices and PBS subsidy status can change; advise patients to check major chains and online pharmacy credentials.

Rural patients may face longer wait times; consider prescribing an initial supply large enough for follow‑up and use telehealth for ongoing review where appropriate.

• Patient Actions If Cost/Access Is A Barrier:
  • Ask the pharmacist about generics or therapeutic alternatives on the PBS.
  • Check with multiple chains for stock and price differences.
  • Discuss authority prescriptions or alternative agents with the prescriber.

Registration & Regulation (Australia)

TGA Approval

Clinicians should verify tizanidine products on the TGA ARTG for approved presentations and indications before prescribing.

Imported brands may be available under permits or via the Special Access Scheme when local supplies are unavailable.

PBS Subsidy Details

PBS listing status can change and authority requirements may apply for subsidy eligibility.

If a product is not PBS‑listed for an indication, discuss cost and alternative PBS‑funded options with the patient.

• Regulatory Checks:
  • ARTG number for the specific product.
  • PBS item code and whether authority prescription is needed.
  • Confirm pharmacovigilance reporting pathways for adverse events.

Definitions For Patient Leaflets:

• ARTG — Australian Register of Therapeutic Goods.
• PBS — Pharmaceutical Benefits Scheme subsidy listing.
• Special Access Scheme — pathway for individual importation of unapproved medicines in exceptional circumstances.

Storage & Handling (Practical For Australian Climate)

Household Storage In Australian Climate (Heat/Humidity)

Store tizanidine at controlled room temperature between 20–25°C (68–77°F) and protect from moisture and light.

Do not store in bathrooms or cars where heat and humidity can be high, especially in summer.

For mail delivery to remote areas plan shipments to avoid exposure to extreme heat during transit.

Cold‑Chain Handling For Pharmacies

Tizanidine is not a cold‑chain product but should be stored per the manufacturer SPC away from direct sunlight and excessive humidity.

Document storage conditions during transport and advise patients on safe disposal of old or unused medicine.

• Patient Home Storage Checklist:
  • Keep in original packaging.
  • Store below 25°C and away from moisture.
  • Keep out of reach of children.

Guidelines For Proper Use (Pharmacist Counselling & Patient Steps)

Australian Pharmacist Counselling Style

Confirm the indication and prior therapies before dispensing.

Review the full medication list for interactions, especially fluvoxamine and ciprofloxacin.

Explain starting dose and titration plan and give clear written dosing instructions.

Warn about sedation and driving, and arrange baseline and follow‑up monitoring for BP, pulse and LFTs.

Provide emergency instructions and a written dosing schedule to carry or keep at home.

Patient Advice From PBS And National Health Authorities

Reinforce that tizanidine is prescription‑only and that missed dose rules and overdose actions should be followed as advised.

Encourage reporting adverse effects to the pharmacist or GP, and advise reporting serious events to the TGA adverse event system.

• Patient Checklist:
  • Who to call: pharmacist for minor queries, GP for concerning effects, emergency services for collapse or breathing difficulty.
  • What to watch for: severe drowsiness, fainting, jaundice, slow pulse.
  • Keep a printable dosing card with times and actions for missed doses.

Delivery Across Australia